{"id":416692,"date":"2021-01-19T08:18:22","date_gmt":"2021-01-19T13:18:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416692"},"modified":"2021-01-19T08:18:22","modified_gmt":"2021-01-19T13:18:22","slug":"xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/","title":{"rendered":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy"},"content":{"rendered":"<h2>\nAppointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D.<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, Jan.  19, 2021  (GLOBE NEWSWIRE) &#8212; XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., Dean of Dell Medical School, Vice President for Medical Affairs, University of Texas, Austin. Members of the board include Greg Albers, M.D., Director of Stanford University Stroke Center, and Brett Cucchiara, M.D., Director of the Neurovascular Ultrasound Laboratory at the University of Pennsylvania.<\/p>\n<p align=\"justify\">The CMAB is providing expert Medical and Clinical guidance for XBiotech\u2019s new candidate neuroprotectant, anti-inflammatory True Human\u2122 antibody therapy to treat stroke. Dr. Clay Johnston commented, \u201cWhile we have done a great job in increasing reperfusion after stroke, we have failed to address the downstream injury that nearly always occurs. Inflammation is a key part of that injury and blocking IL-1\u237a has real potential in further improving outcomes for patients. Once again, I\u2019m excited about the potential for a neuroprotective agent.\u201d<\/p>\n<p align=\"justify\">Together with the CMAB, the Company believes it has the potential to provide groundbreaking antibody therapies to patients that will help reduce the impact of strokes and improve recovery of stroke victims. Currently, no neuroprotectant treatment has been approved for the damaging effects of reperfusion injury, representing an extraordinary unmet medical need.<\/p>\n<p align=\"justify\">John Simard, President and CEO of XBiotech, commented, \u201cI am indeed honored to have the support of such distinguished medical experts assisting XBiotech in developing a True Human antibody which we believe has unprecedented potential as a neuroprotectant for patients who experience ischemic strokes. We plan to expedite clinical development of this unique new drug.\u201d<\/p>\n<p align=\"justify\">\n        <u>XBiotech\u2019s Cerebrovascular Medical Advisory Board Includes:<\/u>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Clay Johnston M.D., Ph.D. currently serves as the inaugural dean of Dell Medical School at the University of Texas in Austin. As a neurologist specializing in stroke care and research, he has published extensively in the prevention and treatment of stroke and transient ischemic attack. He has led several large cohort studies and three international multi-center randomized trials. Dr. Johnston is a graduate of Amherst College and Harvard Medical School. He later received his Ph.D. in epidemiology from the University of California, Berkeley, and was a resident in Neurology at UCSF, where he trained in Vascular Neurology. Dr. Johnston has received national accolades for his research and was elected to the National Academy of Medicine in 2019.\n<\/li>\n<li style=\"text-align:justify\">Greg W. Albers, M.D. is a stroke and vascular neurologist and currently serves as the Director of the Stanford Stroke Center at Stanford Medical Center. Dr. Albers is a Coyote Foundation Professor and a Professor, by courtesy, of Neurosurgery and Neurological Sciences at Stanford University. Dr. Albers\u2019 primary research focus is the diagnosis, management, and prevention of ischemic stroke. A prolific and distinguished researcher, he has authored more than 450 articles on topics related to cerebrovascular disease in peer-reviewed journals.\n<\/li>\n<li style=\"text-align:justify\">Brett L. Cucchiara M.D. is a Professor of Neurology and serves as the Director of the Neurovascular Ultrasound Laboratory at the University of Pennsylvania. He specializes in cerebrovascular disease and has extensive experience in stroke clinical trials and biomarker research. Dr. Cucchiara is a member of the American Board of Psychiatry and Neurology.<\/li>\n<\/ul>\n<p align=\"justify\">Brain reperfusion, or opening of the clogged artery, is the cornerstone of emergency treatment for ischemic stroke. However, opening of a clogged artery is associated with a rapid induction of inflammation where the returning blood supply downstream of the clogged artery begins to recirculate in the brain. The brain injury inflicted by the inflammation can be devastating. There is presently no approved drug to reduce injury from reperfusion. XBiotech previously announced a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gbqpVY53e0vLwcBwOOvo2BkeesWYQI6oERpVyowzWA_as-qQT7r4W7jBYRb5WkNckQFoPryBye-1vqhW425-QfayVX2wZ8h4DCgp06RNn-590mSGH5yIBzOCB43ULYqN1gFak4FG_P-0-f9jh6tjgA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">publication<\/a>, in animal models of stroke, which described a significant reduction in brain injury when an IL-1\u237a neutralizing antibody was used to inhibit inflammation prior to unblocking of the clogged artery.<\/p>\n<p align=\"justify\">On December 30, 2019, XBiotech sold a True Human\u2122 anti-inflammatory antibody in a $1.35 billion transaction. The Company has since worked vigorously to bring a new line of True Human\u2122 anti-inflammatory therapies to the clinic in 2021. XBiotech is now developing a novel True Human\u2122 antibody therapy that neutralizes interleukin-1 alpha (IL-1\u237a) as a neuroprotectant. IL-1\u237a is a trigger in the onset of inflammation. When inflammation is deregulated, or in situations of acute injury, such as that which occurs after reperfusion (the resumption of blood flow after unblocking of an artery), IL-1\u237a enhances the inflammation that leads to worsening of the injury.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0XBiotech<\/strong><br \/>\n        <br \/>XBiotech\u00a0is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies.\u00a0XBiotech\u00a0currently is advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Utilizing natural human immunity as a source of new medicines offers the potential to redefine the standards of care for a wide range of diseases.<\/p>\n<p align=\"justify\">On\u00a0December 30, 2019\u00a0XBiotech\u00a0sold an IL-1\u237a blocking True Human\u2122 antibody that had been used successfully in a number of clinical trials. The sale of the antibody generated\u00a0$750 million\u00a0in upfront cash and up to\u00a0$600 million\u00a0in potential milestone payments. The Company retained the right to pursue the development of True Human\u2122 antibodies targeting IL-1\u237a for all areas of medicine outside of dermatology. While the Company previously was focused on a single True Human<sup>\u2122<\/sup>\u00a0antibody targeting IL-1\u237a, it now plans to develop multiple product candidates, which will target IL-1\u237a in specific areas of medicine.<\/p>\n<p align=\"justify\">In addition to recent sale of its anti-IL-1\u237a antibody,\u00a0XBiotech\u00a0now has other revenue sources. Commencing\u00a0January 1, 2020\u00a0XBiotech\u00a0began using its proprietary manufacturing technology to produce clinical drug product for a major\u00a0Pharmaceutical Company\u00a0under a two-year supply agreement. In addition,\u00a0XBiotech\u00a0is providing clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The financial strength generated from the sale and contract operations is enabling\u00a0XBiotech\u00a0to expand both its anti-IL-1\u237a product development and infectious disease programs.<\/p>\n<p align=\"justify\">To accelerate advance of the Company\u2019s pipeline, the Company is expanding its existing manufacturing and research center, and planning to build an additional 30,000ft<sup>2<\/sup>\u00a0infectious disease research &amp; development center on its 48-acre property in\u00a0Austin, TX\u00a0which is wholly owned by the Company. The expansion and new building will be in addition to the present custom-built 33,000ft<sup>2<\/sup>\u00a0combined manufacturing and R&amp;D facility that currently exists on the campus.\u00a0XBiotech\u00a0owns the 48-acre campus\u2014and all structures on the property\u2014debt-free and envisions further expansion of facilities. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5G2mnvIXiYX2UZe4A7-IrV6pR3kH8nSfp_8J5zgsUhBAusLVCwgVKSuh0ojAYEmHeh-lE23ecXO6qMhYPe6LnQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.xbiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About True Human\u2122 Therapeutic Antibodies<\/strong><br \/>\n        <br \/>XBiotech\u2019s True Human\u2122 antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases. (Unlike all commercially available antibodies, which are called \u201cHumanized\u201d or \u201cFully Human\u201d, XBiotech\u2019s\u00a0True Human\u2122 antibodies are directly sourced from the natural human immune response for specific diseases without modification, and thereby have not been shown to cause immunogenicity.) With discovery and clinical programs across multiple disease areas, XBiotech\u2019s True Human antibodies have the potential to harness the body\u2019s natural immunity to fight disease with increased safety, efficacy and tolerability.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements, including declarations regarding management&#8217;s beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;contemplate,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;intend&#8221; or &#8220;continue&#8221; or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the &#8220;Risk Factors&#8221; section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Ashley Otero<br \/>aotero@xbiotech.com<br \/>512-386-2930<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f1f31fe0-3a20-4f83-a7a7-932dde0ff786\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., Dean of Dell Medical School, Vice President for Medical Affairs, University of Texas, Austin. Members of the board include Greg Albers, M.D., Director of Stanford University Stroke Center, and Brett Cucchiara, M.D., Director of the Neurovascular &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416692","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., Dean of Dell Medical School, Vice President for Medical Affairs, University of Texas, Austin. Members of the board include Greg Albers, M.D., Director of Stanford University Stroke Center, and Brett Cucchiara, M.D., Director of the Neurovascular &hellip; Continue reading &quot;XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T13:18:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy\",\"datePublished\":\"2021-01-19T13:18:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/\"},\"wordCount\":1454,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/\",\"name\":\"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\",\"datePublished\":\"2021-01-19T13:18:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/","og_locale":"en_US","og_type":"article","og_title":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk","og_description":"Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) &#8212; XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., Dean of Dell Medical School, Vice President for Medical Affairs, University of Texas, Austin. Members of the board include Greg Albers, M.D., Director of Stanford University Stroke Center, and Brett Cucchiara, M.D., Director of the Neurovascular &hellip; Continue reading \"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T13:18:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy","datePublished":"2021-01-19T13:18:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/"},"wordCount":1454,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/","name":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=","datePublished":"2021-01-19T13:18:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzNzc3NyMzOTM0NjA5IzIwMTczNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xbiotech-announces-cerebrovascular-medical-advisory-board-development-of-new-stroke-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XBiotech Announces Cerebrovascular Medical Advisory Board &amp; Development of New Stroke Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416692"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}